Amrinone (Amrinon)

A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.

Also Known As:

Networked: 346 relevant articles (51 outcomes, 58 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Furuya, Hitoshi: 3 articles (09/2006 - 07/2002)
2.	Inoue, Satoki: 3 articles (09/2006 - 07/2002)
3.	Kawaguchi, Masahiko: 2 articles (10/2002 - 07/2002)
4.	Kitaguchi, Katsuyasu: 2 articles (10/2002 - 07/2002)
5.	Sakamoto, Takanori: 2 articles (10/2002 - 07/2002)
6.	Gebhard, M M: 2 articles (09/2000 - 09/2000)
7.	Martin, E: 2 articles (09/2000 - 09/2000)
8.	Schmidt, H: 2 articles (09/2000 - 09/2000)
9.	Schmidt, W: 2 articles (09/2000 - 09/2000)
10.	Tinelli, M: 2 articles (09/2000 - 09/2000)

Related Diseases

1.	Heart Failure 07/22/1985 - "Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption. " 07/01/1981 - "Amrinone, a new inotropic agent, has been shown to be beneficial in patients with congestive heart failure. " 11/01/1984 - "Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure." 03/01/1987 - "Thus, intravenous amrinone proved effective in patients with severe heart failure, with maximal effects being obtained in doses of 3 mg X min-1." 05/01/1984 - "It is concluded that amrinone is effective in the long-term treatment of chronic cardiac failure."
2.	Pulmonary Hypertension 09/01/1986 - "The aim of this study was to investigate the haemodynamic effects of amrinone in patients with pulmonary hypertension and impaired right ventricular function. " 08/01/1996 - "Lungs were examined for immunohistochemical evidence of PDGF and bFGF, and hearts were examined for effects of pulmonary hypertension and amrinone. " 11/01/1993 - "Effect of amrinone during group B Streptococcus-induced pulmonary hypertension in piglets." 10/01/1993 - "The sole child with postoperative pulmonary hypertension had a beneficial decrease in pulmonary artery pressure, increase in cardiac index, and stable systemic blood pressure during amrinone use. " 12/01/1989 - "The role of amrinone in potential heart transplant patients with pulmonary hypertension."
3.	Low Cardiac Output 01/01/1991 - "The efficacy of amrinone was assessed in the treatment of low cardiac output states occurring within 24 h after mitral valve replacement in an open prospective trial. " 01/01/1991 - "[Hemodynamic effects of amrinone in low cardiac output after mitral valve replacement]." 08/01/1990 - "Amrinone in perioperative low cardiac output syndrome." 12/01/1989 - "Intravenous amrinone has been shown clinically to improve hemodynamic status remarkably in the patient experiencing a low cardiac output syndrome, by increasing CO while decreasing filling pressures and pulmonary arterial pressures, without increasing myocardial O2 demand. " 12/01/1989 - "Amrinone: contemporary management of the low cardiac output syndrome. "
4.	Coronary Artery Disease (Coronary Atherosclerosis) 05/01/1994 - "We have studied the effects of amrinone on left and right ventricular haemodynamics in patients with impaired ventricular performance caused by coronary artery disease. " 12/01/1986 - "Peripheral hemodynamics and metabolic parameters were studied in 12 healthy volunteers (mean = 24.6 years) and in 12 patients with coronary artery disease (mean = 51.1 years) at rest and after isometric handgrip exercise both before and after application of amrinone (1.5 mg/kg body weight i.v.). " 07/01/1980 - "Accordingly, the hemodynamic, myocardial metabolic and ECG responses to amrinone (2.5 mg/kg i.v. over 1 hour) were measured in nine patients with congestive heart failure secondary to coronary artery disease. " 07/01/1980 - "Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease." 11/15/1996 - "Augmentation of myocardial contraction by amrinone in patients with chronic coronary artery disease and severe baseline left ventricular dysfunction predicts improvement in left ventricular ejection fraction after coronary artery bypass graft surgery."
5.	Myocardial Ischemia (Ischemic Heart Diseases) 02/01/1987 - "The effect of the positive inotropic agent amrinone on anatomic infarct size induced by coronary artery occlusion and reperfusion in dogs is unknown, although previous studies have shown that amrinone increases indices of myocardial ischemia during very brief coronary artery occlusions. " 10/01/1992 - "The incidence of myocardial ischemia as detected by Holter monitor was 36% with amrinone and 33% with dobutamine. " 07/01/1980 - "The amrinone-induced hemodynamic improvement in patients with congestive heart failure secondary to coronary artery disease was associated with reductions in MVO2 and CBF and no evidence of myocardial ischemia." 12/01/1993 - "Effect of amrinone and milrinone on myocardial ischemia extent and infarct size in isolated rabbit hearts." 12/01/1984 - "Clinically, amrinone therapy was complicated by sustained symptomatic ventricular tachycardia in four patients, worsening myocardial ischemia in four patients, and worsening congestive heart failure in eight patients, all of whom had been stable before entry into the study; only three of the 31 patients improved clinically. "

Related Drugs and Biologics

1.	Dobutamine
2.	Milrinone (Primacor)
3.	Vasodilator Agents (Vasodilators)
4.	Phosphodiesterase Inhibitors
5.	Type 3 Cyclic Nucleotide Phosphodiesterases
6.	Epinephrine (Adrenaline)
7.	Sympathomimetics (Sympathomimetic Amines)
8.	pirbuterol (Maxair)
9.	Cardiotonic Agents (Cardiac Stimulants)
10.	Oxygen (Dioxygen)

Related Therapies and Procedures

1.	Therapeutics
2.	Cardiopulmonary Bypass (Heart-Lung Bypass)
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Oral Administration
5.	Intravenous Administration